Trial Profile
Multicentre, Single-arm, Open Label Clinical Trial Intended to Provide Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen and to Document Safety of Cabazitaxel in These Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary) ; Prednisolone; Prednisone
- Indications Prostate cancer
- Focus Expanded access; Registrational; Therapeutic Use
- Sponsors Sanofi
- 19 Jun 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 06 Jan 2015 Planned End Date changed from 1 Dec 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov.
- 06 Jan 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov.